Showing 3631-3640 of 4764 results for "".
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri
- Galderma Global Survey Assesses Burden of Rosaceahttps://practicaldermatology.com/news/galderma-global-survey-assesses-burden-of-rosacea/2457732/Recently released findings from Galderma’s global survey on the true burden of rosacea suggest a need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea. An expert-authored report entitled Rosacea:
- Luma Therapeutics Launches Novel illuvinate Phototherapy Systemhttps://practicaldermatology.com/news/luma-therapeutics-launches-novel-illuvinate-phototherapy-system/2457736/Luma Therapeutics has launched illuvinate as an innovative and modern twist on the Goeckerman regimen. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globules, illuvinate increases the skin's hydration, decreases inflammation, and suppresses overacti
- New Dermatologic Surgery Textbook by McGraw-Hill Enters Second Printing Less Than One Week After Publicationhttps://practicaldermatology.com/news/new-dermatologic-surgery-textbook-by-mcgraw-hill-enters-second-printing-less-than-one-week-after-publication/2457746/McGraw-Hill has just released Jonathan Kantor’s new 1,440-page textbook, Dermatologic Surgery, the most comprehensive and richly illustrated dermatologic surgery textbook ever published, and the first new major multimedia textbook in the field in 13 years. With section editors
- Psoriatic Arthritis Awareness Project Launcheshttps://practicaldermatology.com/news/psoriatic-arthritis-awareness-project-launches/2457751/In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awareness Project. The PsA Awareness Project is a set of patient films that highlight the impo
- Biotin Supplements Caused Misleading Test Results, Almost Led to an Unnecessary Procedurehttps://practicaldermatology.com/news/biotin-supplements-caused-misleading-test-results-almost-led-to-an-unnecessary-procedure/2457758/A new case report in the Journal of the Endocrine Society documents how a patient's use of a biotin supplement, caused her to have clinically misleading test results, whic
- New Guidelines May Slightly Increase Reliability, Accuracy of Melanoma Diagnoseshttps://practicaldermatology.com/news/new-guidelines-may-slightly-increase-reliability-accuracy-of-melanoma-diagnoses/2457759/New guidelines may slightly increase reliability and accuracy of melanoma diagnoses, a new study in JAMA Network Open shows. The American Joint Committee on Cancer recently updated its guidelines for melanoma, and the study researchers found that when pathologists used the new gu
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat
- Daily Aspirin Linked to Higher Melanoma Risk in Menhttps://practicaldermatology.com/news/daily-aspirin-linked-to-higher-melanoma-risk-in-men/2457779/Men who take once-daily aspirin have nearly double the risk of melanoma compared to men who don’t, reports a new Northwestern Medicine study. Women, however, do not have an increased risk in this large patient population, the study showed. The study collected medical record